These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 25592326

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina.
    Lee S, Hong HK, Song JS, Jeong SI, Chung JY, Woo SJ, Park KD.
    Acta Biomater; 2023 Nov; 171():273-288. PubMed ID: 37739248
    [Abstract] [Full Text] [Related]

  • 3. Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab.
    Jiang P, Jacobs KM, Ohr MP, Swindle-Reilly KE.
    Mol Pharm; 2020 Jul 06; 17(7):2570-2584. PubMed ID: 32484677
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In situ antibody-loaded hydrogel for intravitreal delivery.
    Awwad S, Abubakre A, Angkawinitwong U, Khaw PT, Brocchini S.
    Eur J Pharm Sci; 2019 Sep 01; 137():104993. PubMed ID: 31302214
    [Abstract] [Full Text] [Related]

  • 7. A biocompatible reverse thermoresponsive polymer for ocular drug delivery.
    Balachandra A, Chan EC, Paul JP, Ng S, Chrysostomou V, Ngo S, Mayadunne R, van Wijngaarden P.
    Drug Deliv; 2019 Dec 01; 26(1):343-353. PubMed ID: 30905169
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications.
    Liu J, Zhang X, Li G, Xu F, Li S, Teng L, Li Y, Sun F.
    Int J Nanomedicine; 2019 Dec 01; 14():8819-8834. PubMed ID: 31819410
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intravitreal bevacizumab effects on VEGF levels in distant organs: an experimental study.
    Dınc E, Yıldırım O, Necat Yılmaz S, Canacankatan N, Ayaz L, Ozcan T, Temel GO.
    Cutan Ocul Toxicol; 2014 Dec 01; 33(4):275-82. PubMed ID: 24228870
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
    Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, Nugent AK, Hirooka K, Baba T.
    Invest Ophthalmol Vis Sci; 2009 Oct 01; 50(10):4807-13. PubMed ID: 19324856
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.